Renaissance Technologies LLC Sells 141,107 Shares of Protara Therapeutics, Inc. $TARA

Renaissance Technologies LLC lessened its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 52.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 125,700 shares of the company’s stock after selling 141,107 shares during the period. Renaissance Technologies LLC owned approximately 0.23% of Protara Therapeutics worth $655,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Walleye Capital LLC increased its position in Protara Therapeutics by 204.0% during the first quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after acquiring an additional 297,525 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Protara Therapeutics by 133.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after purchasing an additional 304,110 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Protara Therapeutics by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 129,671 shares of the company’s stock valued at $676,000 after purchasing an additional 36,149 shares during the last quarter. AIGH Capital Management LLC purchased a new stake in Protara Therapeutics in the 1st quarter worth about $8,454,000. Finally, Assenagon Asset Management S.A. raised its position in Protara Therapeutics by 84.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 567,621 shares of the company’s stock worth $2,957,000 after purchasing an additional 259,287 shares during the period. 38.13% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Oppenheimer boosted their target price on Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, May 20th. JPMorgan Chase & Co. reduced their price target on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. UBS Group reissued a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Friday, July 17th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Protara Therapeutics Price Performance

Protara Therapeutics stock opened at $3.97 on Monday. The stock has a market cap of $234.63 million, a price-to-earnings ratio of -2.94 and a beta of 1.50. Protara Therapeutics, Inc. has a 1 year low of $2.97 and a 1 year high of $7.82. The firm has a 50-day moving average of $4.02 and a two-hundred day moving average of $5.01.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). Research analysts expect that Protara Therapeutics, Inc. will post -1.48 earnings per share for the current year.

Protara Therapeutics Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.